Synonyms: DF2726 (acid form) | DF2726A (sodium salt)
Compound class:
Synthetic organic
Comment: DF2726 is a non-competitive, negative allosteric modulator of CXCL8 (IL-8) signalling via its endogenous chemokine receptors CXCR1 and CXCR2 [1]. Its chemical structure was claimed in patent EP3192504A1 [2], and it appears to be structurally related to DF2755A. Activation of the IL-8 pathway has been linked to the development of chemotherapy-induced neuropathic pain. It is predicted that inhibition of this mechanism might offer clinical utility for cancer patients who experience chemotherapy-induced peripheral neuropathy [1].
DF2726A refers to the sodium salt formulation that is used for in vitro and in vivo studies. |
|
References |
1. Brandolini L, Castelli V, Aramini A, Giorgio C, Bianchini G, Russo R, De Caro C, d'Angelo M, Catanesi M, Benedetti E et al.. (2019)
DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Sci Rep, 9 (1): 11729. [PMID:31409858] |
2. Brandolini L, Ruffini P, Allegretti M. (2018)
Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy. Patent number: EP3192504A1. Assignee: Dompe Farmaceutici SpA. Priority date: 15/01/2016. Publication date: 19/07/2018. |